The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system

• Egile Nagusiak: Wei Wei (Egilea), Liang Huang (Egilea), Yingtao Bai (Egilea), En Chang (Egilea), Jinfeng Liu (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2024-07-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

BackgroundOseltamivir and baloxavir marboxil are the two primary oral drugs approved by the Food and Drug Administration (FDA) for treating influenza. Limited real-world evidence exists on their adverse events in children. The purpose of this study was to explore the adverse event (AE) profiles of o...